89BIO (ETNB)
(Real Time Quote from BATS)
$8.31 USD
-0.04 (-0.48%)
Updated Jul 22, 2024 09:34 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ETNB 8.31 -0.04(-0.48%)
Will ETNB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ETNB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ETNB
All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy
Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success
ETNB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
89BIO (ETNB) Just Overtook the 200-Day Moving Average
Other News for ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Buy Rating Affirmed on 89bio Due to Pegozafermin’s Promising Trial Results and Strategic Position in NASH Treatment Landscape
Buy Rating Affirmed for 89bio Following Promising Pegozafermin Trial Results
Madrigal, 89bio, Akero slip after Eli Lilly MASH data released